Nu-Med Plus (NUMD) Return on Invested Capital (2017 - 2019)

Nu-Med Plus (NUMD) posted Return on Invested Capital of 0.73% for Q3 2019, down 20.6% sequentially from 0.61% in Q2 2019.

Nu-Med Plus (NUMD) Return on Invested Capital (2017 - 2019) Analysis & Trends

Nu-Med Plus has reported Return on Invested Capital for 3 years, with the latest figure at 0.73% in Q3 2019.

Quarterly Return on Invested Capital changed N/A year-over-year to 0.73% in Q3 2019, while the trailing twelve-month figure through Sep 2019 was 0.73% (changed N/A YoY) and the FY2018 annual result came in at 1.15%, changed N/A from the prior year.
Return on Invested Capital declined to 0.73% in Q3 2019 per NUMD's latest filing, from 0.61% in the prior quarter.
Over five years, Return on Invested Capital peaked at 0.3% in Q4 2018 and troughed at 0.73% in Q3 2019.
A 3-year average of 0.5% and a median of 0.43% in 2017 frame the typical range for Return on Invested Capital.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Abbott Laboratories	199.28 Bn	193.68 Bn	7.27 Bn	0.01%
2	Stryker	129.49 Bn	126.02 Bn	4.50 Bn	0.01%
3	Medtronic	119.55 Bn	110.33 Bn	6.41 Bn	0.01%
4	Boston Scientific	73.67 Bn	73.13 Bn	3.85 Bn	0.00%
5	Edwards Lifesciences	52.28 Bn	48.03 Bn	1.35 Bn	-
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn	-
7	GE HealthCare Technologies	34.13 Bn	32.02 Bn	2.18 Bn	0.01%
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn	0.00%
9	Steris	23.17 Bn	22.69 Bn	684.20 Mn	0.04%
10	Nu-Med Plus	2.03 Mn	2.02 Mn	-	-

Download Data